Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067737863> ?p ?o ?g. }
- W2067737863 endingPage "2273" @default.
- W2067737863 startingPage "2268" @default.
- W2067737863 abstract "Purpose To determine the tolerability and feasibility of double-cycle, high-dose chemotherapy followed by peripheral blood stem-cell transplantation (PBSCT) after conventional chemotherapy or chemoradiotherapy for small cell lung cancer (SCLC). Patients and methods Patients with previously untreated SCLC received two cycles of cisplatin, 80 mg/m2, and etoposide, 300 mg/m2 (cisplatin-etoposide [PE]). Later, they were administered high-dose etoposide, 1,500 mg/m2, followed by granulocyte colony-stimulating factor for collection of peripheral blood stem cells. After two additional cycles of PE, the patients received high-dose ifosfamide, 10 g/m2, carboplatin, 1,200 mg/m2, and etoposide, 1,000 mg/m2 (ifosfamide-carboplatin-etoposide [ICE]) followed by PBSCT twice at 3-month to 4-month intervals. Patients with limited disease (LD) concurrently received 50 Gy of irradiation with the last two cycles of PE. Results Eighteen patients, including 11 patients with LD, were enrolled. Fifteen patients could receive high-dose ICE followed by PBSCT twice, and 3 patients could receive it once. The median number of CD34+ cells collected was 13.11 × 106/kg. The median numbers of days to neutrophil counts ≥ 500/μL and platelet counts ≥ 50,000/μL were 10 days and 14.5 days after the first PBSCT, and 10 days and 15 days after the second PBSCT, respectively. Grade 3 diarrhea occurred in one cycle, and grade 3 renal toxicity occurred in two cycles. The overall response rate was 100%, with an 83.3% rate of complete or near-complete response. The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. Conclusion Double-cycle, high-dose ICE therapy followed by PBSCT is tolerable and feasible even after conventional chemotherapy or chemoradiotherapy in patients with SCLC. To determine the tolerability and feasibility of double-cycle, high-dose chemotherapy followed by peripheral blood stem-cell transplantation (PBSCT) after conventional chemotherapy or chemoradiotherapy for small cell lung cancer (SCLC). Patients with previously untreated SCLC received two cycles of cisplatin, 80 mg/m2, and etoposide, 300 mg/m2 (cisplatin-etoposide [PE]). Later, they were administered high-dose etoposide, 1,500 mg/m2, followed by granulocyte colony-stimulating factor for collection of peripheral blood stem cells. After two additional cycles of PE, the patients received high-dose ifosfamide, 10 g/m2, carboplatin, 1,200 mg/m2, and etoposide, 1,000 mg/m2 (ifosfamide-carboplatin-etoposide [ICE]) followed by PBSCT twice at 3-month to 4-month intervals. Patients with limited disease (LD) concurrently received 50 Gy of irradiation with the last two cycles of PE. Eighteen patients, including 11 patients with LD, were enrolled. Fifteen patients could receive high-dose ICE followed by PBSCT twice, and 3 patients could receive it once. The median number of CD34+ cells collected was 13.11 × 106/kg. The median numbers of days to neutrophil counts ≥ 500/μL and platelet counts ≥ 50,000/μL were 10 days and 14.5 days after the first PBSCT, and 10 days and 15 days after the second PBSCT, respectively. Grade 3 diarrhea occurred in one cycle, and grade 3 renal toxicity occurred in two cycles. The overall response rate was 100%, with an 83.3% rate of complete or near-complete response. The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. Double-cycle, high-dose ICE therapy followed by PBSCT is tolerable and feasible even after conventional chemotherapy or chemoradiotherapy in patients with SCLC." @default.
- W2067737863 created "2016-06-24" @default.
- W2067737863 creator A5004638944 @default.
- W2067737863 creator A5007114409 @default.
- W2067737863 creator A5008639301 @default.
- W2067737863 creator A5013932077 @default.
- W2067737863 creator A5031697973 @default.
- W2067737863 creator A5041691581 @default.
- W2067737863 creator A5051768163 @default.
- W2067737863 creator A5073976571 @default.
- W2067737863 date "2005-10-01" @default.
- W2067737863 modified "2023-10-06" @default.
- W2067737863 title "Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer" @default.
- W2067737863 cites W1839348318 @default.
- W2067737863 cites W1859960333 @default.
- W2067737863 cites W1900393559 @default.
- W2067737863 cites W1934533231 @default.
- W2067737863 cites W1937807827 @default.
- W2067737863 cites W1954734300 @default.
- W2067737863 cites W2020877355 @default.
- W2067737863 cites W2046789782 @default.
- W2067737863 cites W2074816774 @default.
- W2067737863 cites W2097597328 @default.
- W2067737863 cites W2122995772 @default.
- W2067737863 cites W2123586708 @default.
- W2067737863 cites W2123767004 @default.
- W2067737863 cites W2133390000 @default.
- W2067737863 cites W2133495180 @default.
- W2067737863 cites W2167578480 @default.
- W2067737863 cites W2167970055 @default.
- W2067737863 cites W2173643829 @default.
- W2067737863 cites W2253767836 @default.
- W2067737863 cites W2265303219 @default.
- W2067737863 cites W2287470414 @default.
- W2067737863 cites W2340678921 @default.
- W2067737863 cites W4434567 @default.
- W2067737863 cites W68922528 @default.
- W2067737863 doi "https://doi.org/10.1378/chest.128.4.2268" @default.
- W2067737863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16236883" @default.
- W2067737863 hasPublicationYear "2005" @default.
- W2067737863 type Work @default.
- W2067737863 sameAs 2067737863 @default.
- W2067737863 citedByCount "14" @default.
- W2067737863 countsByYear W20677378632012 @default.
- W2067737863 countsByYear W20677378632014 @default.
- W2067737863 countsByYear W20677378632016 @default.
- W2067737863 countsByYear W20677378632019 @default.
- W2067737863 countsByYear W20677378632021 @default.
- W2067737863 countsByYear W20677378632022 @default.
- W2067737863 crossrefType "journal-article" @default.
- W2067737863 hasAuthorship W2067737863A5004638944 @default.
- W2067737863 hasAuthorship W2067737863A5007114409 @default.
- W2067737863 hasAuthorship W2067737863A5008639301 @default.
- W2067737863 hasAuthorship W2067737863A5013932077 @default.
- W2067737863 hasAuthorship W2067737863A5031697973 @default.
- W2067737863 hasAuthorship W2067737863A5041691581 @default.
- W2067737863 hasAuthorship W2067737863A5051768163 @default.
- W2067737863 hasAuthorship W2067737863A5073976571 @default.
- W2067737863 hasConcept C126322002 @default.
- W2067737863 hasConcept C126894567 @default.
- W2067737863 hasConcept C141071460 @default.
- W2067737863 hasConcept C197934379 @default.
- W2067737863 hasConcept C2776694085 @default.
- W2067737863 hasConcept C2777506904 @default.
- W2067737863 hasConcept C2778119113 @default.
- W2067737863 hasConcept C2778239845 @default.
- W2067737863 hasConcept C2778375690 @default.
- W2067737863 hasConcept C2781451048 @default.
- W2067737863 hasConcept C2911091166 @default.
- W2067737863 hasConcept C71924100 @default.
- W2067737863 hasConcept C90924648 @default.
- W2067737863 hasConceptScore W2067737863C126322002 @default.
- W2067737863 hasConceptScore W2067737863C126894567 @default.
- W2067737863 hasConceptScore W2067737863C141071460 @default.
- W2067737863 hasConceptScore W2067737863C197934379 @default.
- W2067737863 hasConceptScore W2067737863C2776694085 @default.
- W2067737863 hasConceptScore W2067737863C2777506904 @default.
- W2067737863 hasConceptScore W2067737863C2778119113 @default.
- W2067737863 hasConceptScore W2067737863C2778239845 @default.
- W2067737863 hasConceptScore W2067737863C2778375690 @default.
- W2067737863 hasConceptScore W2067737863C2781451048 @default.
- W2067737863 hasConceptScore W2067737863C2911091166 @default.
- W2067737863 hasConceptScore W2067737863C71924100 @default.
- W2067737863 hasConceptScore W2067737863C90924648 @default.
- W2067737863 hasIssue "4" @default.
- W2067737863 hasLocation W20677378631 @default.
- W2067737863 hasLocation W20677378632 @default.
- W2067737863 hasOpenAccess W2067737863 @default.
- W2067737863 hasPrimaryLocation W20677378631 @default.
- W2067737863 hasRelatedWork W1988562881 @default.
- W2067737863 hasRelatedWork W2054697909 @default.
- W2067737863 hasRelatedWork W2073498983 @default.
- W2067737863 hasRelatedWork W2147316169 @default.
- W2067737863 hasRelatedWork W2279957943 @default.
- W2067737863 hasRelatedWork W239195424 @default.
- W2067737863 hasRelatedWork W2789166760 @default.
- W2067737863 hasRelatedWork W4241719605 @default.
- W2067737863 hasRelatedWork W4246778165 @default.